Information about risk, prevention, screening, symptoms, diagnosis, treatment, and support for all cancers Information about cancer treatment, including surgery, chemotherapy, radiation therapy, clinical trials, proton therapy, complementary medicine, and cutting edge technologies.
Ways for cancer patients and caregivers to cope with cancer, side effects, nutrition, general cancer support issues, grief/end of life issues, and shared survivor's experiences.
Support and Coping with Cancer / Side Effects
The Abramson Cancer Center of the University of Pennsylvania
Last Modified: December 18, 2005
The purpose of this study is to test the effects of twice-weekly strength training on lymphedema symptoms and arm measurements, as well as quality of life for breast cancer survivors. The knowledge gained from this study may influence exercise recommendations for breast cancer survivors as well as help to promote a healthier lifestyle following treatment of breast cancer.
Lymphedema is one of the most common and often feared conditions associated with breast cancer treatment. There are an estimated 2-400,000 diagnosed cases in the United States. Those who experience lymphedema may have limited movement of their arms, a decrease in muscle strength, and restricted activity in daily life. Survivors may find lymphedema more distressing than a mastectomy as it is more difficult to hide the swelling and limited functioning of the arm.
Although there is no evidence to show that strength training exercise is harmful to breast cancer survivors, current clinical guidelines advise against participating in any vigorous upper body exercise, and in particular, lifting objects that weigh more than 5 to 15 pounds. Strength training can allow women to gradually increase their strength in a supervised setting, making it less likely that daily life activities like shoveling snow or carrying children would harm the lymphatic system and the arm.
Our research study is based on a smaller study involving progressive twice-weekly strength training in 81 recent breast cancer survivors. One group of women performed the strength training exercises for six months compared to a group of women who did not do strength training. In the group of women who did strength training, no one developed lymphedema, or experienced a worsening of symptoms if they had already been diagnosed with lymphedema. This information, along with other research on this topic, tells us that a larger study is needed to look at the effects of twice-weekly progressive strength training on lymphedema symptoms and the lymphatic system, as well as quality of life issues, compared to a non-exercising group of survivors. We will recruit 288 survivors (144 with lymphedema, 144 without lymphedema) 1-15 years post-breast cancer diagnosis to participate in this exercise intervention. The knowledge gained from this study may impact recommendations for therapy, participation in activities of daily living, and recommendations for exercise for health promotion in breast cancer survivors.
This research will take place in the Philadelphia, PA metropolitan area. All participants receive a free one year membership to a gym/fitness center in the metro region, access to a qualified fitness trainer, access to a physical therapist, and financial compensation. We are looking to recruit women who have been diagnosed 1 – 15 years ago and have had at least 2 lymph nodes removed during treatment. For more information about this study, or to see if you are eligible, please contact Amy Rogerino at 215-898-5112 or e mail her at arogerin@cceb.med.upenn.edu.
Dr. Giantonio discusses the privileges bestowed on physicians in our society and the dangers of this. Read more.
Cancer Types
Bone Cancer
Brain Tumors
Breast Cancer
Carcinoid Tumors
Endocrine System Cancers
Gastrointestinal Cancers
Gynecologic Cancers
Head and Neck Cancers
Leukemia
Lung Cancers
Lymphomas
Myelomas
Pediatric Cancers
Penile Cancer
Prostate Cancer
Sarcomas
Skin Cancers
Testicular Cancer
Thyroid Cancer
Urinary Tract Cancers
OncoLink Vet
Cancer Treatment
Biologic Therapy
Bone Marrow Transplants
Chemotherapy
Clinical Trials
Complementary Medicine
Gene Therapy
General Treatment Concerns
Hormone Therapy
PDT Center
Proton Therapy
Radiation Oncology
Surgical Oncology
Targeted Therapies
Vaccine Therapies
Cancer Support
Caregivers
Hospice Care and Bereavement
Nutrition and Cancer
Sexuality & Fertility
Side Effects
Support
Survivorship
Exercise and Cancer
Cancer Resources
Cancer News
OncoLink University
Nurses' Notes
Conferences
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
LGBT Resources
NCI Resources
Global Resources
Cancer Resource List
Resources for Young Adults
OncoLink Media Library
OncoLink TV
Book, Music and Video Reviews
Ask the Experts
Brown Bag Chat
Tracy's Corner
About OncoLink
About OncoLink
Giving to OncoLink
Contact Information
Usage Policy
Editorial Board
How to Partner with OncoLink
Link to OncoLink
Mission Statement
Calcium Leucovorin, Citrovorum Factor, Folinic Acid
Cladribine (2-CDA, Leustatin®)
Cyclophosphamide (Cytoxan®, Neosar®, Endoxan®)
Cyclosporine (Neoral®, Sandimmune®, Restasis®, Gengraf®)
Cytarabine (Cytosar-U®, Ara-C)
Irinotecan (Camptosar®, CPT-11)
Leucovorin (Calcium Leucovorin, Citrovorum Factor, Folinic Acid)
Calcium Leucovorin, Citrovorum Factor, Folinic Acid
Leucovorin (Calcium Leucovorin, Citrovorum Factor, Folinic Acid)
Leuprolide Acetate (Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®) - For Men
Leuprolide Acetate (Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®) - For Women
Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®
Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®
Busulfan (Myleran®, Busulfex®)
Intravesicular Mitomycin (Mutamycin®, Mitomycin-C, given into the bladder)
Mechlorethamine (Mustargen®, Nitrogen Mustard)
mechlorethamine, mustine, Mustargen®
Megestrol (Megace®, Megace-ES®)
Mercaptopurine (Purinethol®, 6-MP)
Methotrexate (Mexate®, Folex®, Rheumatrex®, Amethopterin, MTX)
Mexate®, Folex®, Rheumatrex®, Amethopterin, MTX
Mitomycin (Mutamycin®, Mitomycin-C)
Morphine Sulfate (Given by IV)
Morphine Sulfate (MS Contin®, Avinza®, Kadian®, Oramorph SR®)
MS Contin®, Avinza®, Kadian®, Oramorph SR®
Mutamycin®, Mitomycin-C, given into the bladder
Nitrogen mustard (mechlorethamine, mustine, Mustargen®)
Bendamustine Hydrochloride (Treanda®)
Bexarotene (Targretin®), Oral Formulation
Bexarotene Gel (Targretin® Gel Formulation)
Etoposide (Toposar®, VePesid®, Etopophos®,VP-16)
Thioguanine (6-TG, Thioguanine Tabloid®)
Toposar®, VePesid®, Etopophos®,VP-16
Trelstar LA® and Trelstar Depot®
Tretinoin (Vesanoid®, All-Trans-Retinoic Acid, ATRA)
Triptorelin (Trelstar LA® and Trelstar Depot®)

